fluorouracil has been researched along with Choline Deficiency in 2 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Choline Deficiency: A condition produced by a deficiency of CHOLINE in animals. Choline is known as a lipotropic agent because it has been shown to promote the transport of excess fat from the liver under certain conditions in laboratory animals. Combined deficiency of choline (included in the B vitamin complex) and all other methyl group donors causes liver cirrhosis in some animals. Unlike compounds normally considered as vitamins, choline does not serve as a cofactor in enzymatic reactions. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to observe the effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil (5-FU) in fatty liver models using in vivo 31P-MRS and 19F-MRS and to compare the results." | 7.70 | Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS. ( Harada, M; Koga, K; Nishitani, H; Otsuka, H, 1999) |
| "The purpose of this study was to observe the effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil (5-FU) in fatty liver models using in vivo 31P-MRS and 19F-MRS and to compare the results." | 3.70 | Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS. ( Harada, M; Koga, K; Nishitani, H; Otsuka, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, H | 1 |
| Xu, H | 1 |
| Qiu, S | 1 |
| Chen, J | 1 |
| Lin, Z | 1 |
| Zhu, J | 1 |
| Sun, X | 1 |
| Gao, Q | 1 |
| Chen, X | 1 |
| Xi, C | 1 |
| Huang, D | 1 |
| Zhang, F | 1 |
| Gao, S | 1 |
| Wang, Z | 1 |
| Zhang, J | 1 |
| Liu, X | 1 |
| Ren, G | 1 |
| Tao, X | 1 |
| Li, M | 1 |
| Chen, W | 1 |
| Otsuka, H | 1 |
| Harada, M | 1 |
| Koga, K | 1 |
| Nishitani, H | 1 |
2 other studies available for fluorouracil and Choline Deficiency
| Article | Year |
|---|---|
Choline deficiency-related multi-omics characteristics are susceptible factors for chemotherapy-induced thrombocytopenia.
Topics: Antineoplastic Agents; Choline; Choline Deficiency; Colorectal Neoplasms; Fluorouracil; Humans; Leuk | 2022 |
Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS.
Topics: Animals; Antimetabolites; Choline Deficiency; Fatty Liver; Fluorouracil; Fructose; Liver; Magnetic R | 1999 |